Jill P Smith Selected Research

Cholecystokinin (Pancreozymin)

12/2022	Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis.
1/2021	Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer.
11/2018	Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor.
1/2018	Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.
1/2016	Germline Mutation of the CCK Receptor: A Novel Biomarker for Pancreas Cancer.
1/2016	The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies.
3/2015	Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival.
10/2014	Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.
6/2014	Cholecystokinin mediates progression and metastasis of pancreatic cancer associated with dietary fat.
1/2014	Cholecystokinin and pancreatic cancer: the chicken or the egg?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jill P Smith Research Topics

Disease

33	Neoplasms (Cancer) 05/2023 - 12/2002
31	Pancreatic Neoplasms (Pancreatic Cancer) 05/2023 - 12/2002
15	Fibrosis (Cirrhosis) 01/2024 - 10/2014
10	Inflammation (Inflammations) 10/2021 - 04/2008
8	Neoplasm Metastasis (Metastasis) 12/2021 - 07/2009
7	Adenocarcinoma 01/2018 - 11/2005
5	Carcinogenesis 01/2024 - 01/2019
4	Hepatocellular Carcinoma (Hepatoma) 02/2023 - 01/2020
4	Non-alcoholic Fatty Liver Disease 12/2022 - 01/2020
4	Crohn Disease (Crohn's Disease) 04/2013 - 04/2007
3	Stomach Neoplasms (Stomach Cancer) 01/2021 - 01/2016
3	Pancreatitis 01/2020 - 12/2012
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 07/2011 - 04/2007
2	Colitis 01/2020 - 04/2008
2	Obesity 11/2018 - 06/2014
2	Breast Neoplasms (Breast Cancer) 03/2013 - 03/2010
2	Hepatitis C 06/2004 - 06/2004
2	Chronic Hepatitis C 06/2004 - 06/2004
1	Carcinoma in Situ 01/2023
1	Alcoholic Fatty Liver 12/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 12/2022
1	Liver Cirrhosis (Hepatic Cirrhosis) 03/2022
1	Liver Neoplasms (Liver Cancer) 01/2021
1	Metaplasia 01/2020
1	Chronic Pancreatitis 01/2020
1	Fatty Liver 11/2017

Drug/Important Bio-Agent (IBA)

17	Cholecystokinin Receptors (Cholecystokinin Receptor)IBA 05/2023 - 12/2002
17	GastrinsIBA 10/2022 - 12/2002
14	Peptides (Polypeptides)IBA 10/2021 - 12/2002
13	Cholecystokinin B ReceptorIBA 01/2024 - 12/2002
13	Cholecystokinin (Pancreozymin)IBA 12/2022 - 12/2002
10	Proglumide (Milid)IBA 01/2024 - 11/2018
5	RNA (Ribonucleic Acid)IBA 01/2024 - 12/2002
5	Biomarkers (Surrogate Marker)IBA 12/2022 - 10/2014
5	Opioid Analgesics (Opioids)IBA 01/2020 - 03/2004
5	Naltrexone (ReVia)FDA LinkGeneric 01/2020 - 04/2007
5	Messenger RNA (mRNA)IBA 01/2019 - 12/2002
5	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 11/2005
4	Transaminases (Aminotransferases)IBA 01/2024 - 06/2004
4	CytokinesIBA 01/2024 - 04/2008
4	AntibodiesIBA 02/2023 - 03/2011
4	Proteins (Proteins, Gene)FDA Link 10/2021 - 12/2002
4	Narcotic Antagonists (Opioid Antagonists)IBA 04/2013 - 04/2007
3	MicroRNAs (MicroRNA)IBA 12/2022 - 01/2019
3	VaccinesIBA 01/2021 - 10/2019
3	CalciumIBA 10/2017 - 03/2010
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2010 - 03/2004
3	CCK-C receptorIBA 11/2004 - 12/2002
2	Hydroxyproline (4 Hydroxyproline)IBA 05/2023 - 12/2022
2	Proton Pump InhibitorsIBA 10/2022 - 07/2017
2	ArginaseIBA 10/2021 - 09/2021
2	Gemcitabine FDA Link 09/2021 - 11/2005
2	Cancer VaccinesIBA 01/2021 - 11/2019
2	AcidsIBA 01/2020 - 07/2017
2	Opioid Receptors (Opioid Receptor)IBA 01/2020 - 07/2011
2	Dietary Fats (Dietary Fat)IBA 11/2018 - 06/2014
2	Small Interfering RNA (siRNA)IBA 01/2018 - 07/2009
2	ElementsIBA 01/2018 - 03/2010
2	Opioid Peptides (Opioid Peptide)IBA 07/2011 - 04/2008
2	Amantadine (Aman)FDA LinkGeneric 06/2004 - 06/2004
2	InterferonsIBA 06/2004 - 06/2004
2	Complementary DNA (cDNA)IBA 03/2004 - 12/2002
1	Proline (L-Proline)FDA Link 05/2023
1	Programmed Cell Death 1 ReceptorIBA 02/2023
1	BuffersIBA 02/2023
1	Phosphates (Orthophosphate)IBA 02/2023
1	Alanine Transaminase (SGPT)IBA 12/2022
1	Amino Acids FDA Link 12/2021
1	P-2 (P 2)IBA 10/2021
1	ChymotrypsinogenIBA 10/2021
1	Chymotrypsin FDA Link 10/2021
1	ChemokinesIBA 01/2021
1	Choline (Choline Chloride)IBA 01/2020
1	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2020
1	naltrindoleIBA 01/2020
1	7-benzylidenenaltrexoneIBA 01/2020
1	CeruletideIBA 01/2020
1	Dextrans (Dextran)FDA Link 01/2020
1	EthionineIBA 01/2020
1	Lipase (Acid Lipase)FDA Link 01/2020
1	Matrix Metalloproteinase 7 (Matrilysin)IBA 11/2019
1	PaxillinIBA 11/2019
1	CateninsIBA 11/2019
1	gastrin immunogenIBA 11/2019
1	Protein Kinases (Protein Kinase)IBA 01/2019
1	Metalloproteases (Metalloproteinases)IBA 11/2018
1	FatsIBA 11/2018
1	Immune Checkpoint InhibitorsIBA 01/2018
1	MicellesIBA 01/2018
1	trichrome stainIBA 01/2018
1	Streptozocin (Streptozotocin)FDA Link 11/2017

Therapy/Procedure

24	Therapeutics 01/2023 - 03/2004
7	Drug Therapy (Chemotherapy) 09/2021 - 11/2005
3	Immunotherapy 11/2019 - 01/2018
2	Precision Medicine 03/2013 - 03/2010
2	Photochemotherapy (Photodynamic Therapy) 03/2013 - 04/2012
2	Biological Therapy 03/2010 - 11/2005
1	Lasers (Laser) 01/2019
1	Pancreatectomy 11/2017
1	Islets of Langerhans Transplantation 11/2017